Quantitative clinical proteomics by liquid chromatography - Tandem mass spectrometry: Assessing the platform

Clinical Chemistry

Volumn 56, Issue 2, 2010, Pages 161-164

  Hoofnagle, Andrew N ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; C REACTIVE PROTEIN; LEPTIN; MYELIN BASIC PROTEIN; MYOGLOBIN; PROSTATE SPECIFIC ANTIGEN;

HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEOMICS; QUANTITATIVE ANALYSIS; SHORT SURVEY; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, LIQUID; HUMANS; PROTEOMICS; TANDEM MASS SPECTROMETRY;

EID: 75749100667     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2009.134049     Document Type: Short Survey

References (5)

1. Hoofnagle AN, Wener MH. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods 2009;347:3-11.
2. Carr SA, Anderson L. Protein quantitation through targeted mass spectrometry: the way out of biomarker purgatory? Clin Chem 2008; 54:1749-52.
3. Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009;114:4957-9.
4. Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009;27:633-41.
5. Annesley TM. Ion suppression in mass spectrometry. Clin Chem 2003;49:1041-4.